Key facts
- It has raised $250K.
- Notable investors include Endless Frontier Labs, Purple Ventures (Brno), DEXIC Accelerator, Xenocles.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Stimvia
- ·The full record, as it builds
Funding rounds
No funding rounds for Stimvia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Stimvia
Developer of an electroceutical medical device designed to allow non-invasive treatment of chronic diseases using neuromodulation. The company's device provides optimizations of treatment parameters for personalized therapy to achieve an enhanced effect for each patient, goes beyond overactive bladders and is also used in treating other indicators such as infertility, migraine and cluster headache, erectile dysfunction and premature ejaculation, enabling patients to get access to effective electrochemical treatment.
- Sector
- Healthcare
- HQ
- Ostrava, Czech Republic
- Founded
- 2014
- Employees
- 15
- Website
- stimvia.com/
- Ownership
- Privately Held (backing)
Stimvia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stimvia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stimvia in its N-PORT filings yet. We sweep new filings monthly.